2022 Revenues ($USD) : $36,882,899,400.00
2022 Revenues (foreign currencies) : £29,814,000,000
2022 R&D spend : $6,789,204,800.00
2022 Number of Employees : 69,130
Fiscal Year End : 12/31/22
Leader : CEO Dame Emma Walmsley

GSK had a strong year in 2022, marked by significant corporate changes. In June 2022, it spun off its consumer health division, creating the publicly-traded firm Haleon. GSK reported full-year sales of £29.3 billion, reflecting a 19% increase at actual exchange rates (AER) and a 13% increase at constant exchange rates (CER). Excluding COVID-19 products, sales were up 10% at constant exchange rates. Last year, the company's portfolio shifted toward vaccines and specialty medicines, which accounted for a significant portion of its sales. Its specialty medicines segment generated £11.3 billion in sales in 2022, while vaccines drove £7.9 billion in sales. The company's pipeline comprises 69 vaccines and medicines, with more than 20 new approvals in the past five years. In 2022, GSK debuted Apretude and Cabenuva for HIV treatment and prevention and made progress in developing an RSV vaccine for older adults. Other notable developments include continued progress with the late-stage assets gepotidacin for UTIs, bepirovirsin for chronic hepatitis B, and the acquisitions of Sierra Oncology and Affinivax, further bolstering GSK's pipeline. —BB